• 1. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?
  Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
• 2. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 3. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871

Recent Advances in the Study of 1-(1,1-dioxo-1lambda6-thiolan-3-yl)-3-methylurea (CAS: 33024-64-5): A Comprehensive Research Brief

1-(1,1-dioxo-1lambda6-thiolan-3-yl)-3-methylurea (CAS: 33024-64-5) is a chemically synthesized compound that has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique sulfolane-derived structure, has shown promising potential in various therapeutic applications, including anti-inflammatory and anti-cancer activities. The compound's distinct chemical properties and biological interactions make it a subject of intense investigation, particularly in the context of drug discovery and development.

Recent studies have focused on elucidating the molecular mechanisms underlying the biological effects of 1-(1,1-dioxo-1lambda6-thiolan-3-yl)-3-methylurea. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated its potent inhibitory effects on specific kinase pathways involved in inflammatory responses. The research employed a combination of in vitro assays and molecular docking simulations to identify the compound's binding affinity and selectivity, revealing its potential as a targeted therapeutic agent.

Another notable advancement comes from a 2024 preclinical study, which explored the compound's anti-cancer properties. The study, conducted by a team at the National Cancer Institute, utilized xenograft models to evaluate the efficacy of 1-(1,1-dioxo-1lambda6-thiolan-3-yl)-3-methylurea in suppressing tumor growth. Results indicated a significant reduction in tumor volume, attributed to the compound's ability to induce apoptosis and inhibit angiogenesis. These findings underscore its potential as a candidate for further development in oncology.

In addition to its therapeutic applications, recent research has also investigated the pharmacokinetic and safety profiles of 1-(1,1-dioxo-1lambda6-thiolan-3-yl)-3-methylurea. A 2023 pharmacokinetic study published in Drug Metabolism and Disposition reported favorable absorption and distribution characteristics, with minimal off-target effects observed in animal models. These results suggest that the compound has a promising safety profile, although further clinical trials are necessary to confirm its suitability for human use.

The synthesis and optimization of 1-(1,1-dioxo-1lambda6-thiolan-3-yl)-3-methylurea have also been areas of active research. A recent paper in Organic & Biomolecular Chemistry detailed an improved synthetic route that enhances yield and purity while reducing production costs. This advancement is critical for scaling up production and facilitating future clinical studies.

In conclusion, the growing body of research on 1-(1,1-dioxo-1lambda6-thiolan-3-yl)-3-methylurea highlights its potential as a versatile and effective therapeutic agent. While significant progress has been made in understanding its mechanisms of action and therapeutic benefits, further studies are needed to fully explore its clinical applications. The compound's unique chemical structure and promising biological activities position it as a compelling subject for ongoing and future research in the chemical biology and pharmaceutical fields.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)